Could Geron Corporation (GERN) Lose Strenght? The Stock Increases A Lot Today

March 14, 2018 - By reb123z

Investors sentiment decreased to 0.97 in Q3 2017. Its down 0.24, from 1.21 in 2017Q2. It is negative, as 10 investors sold Geron Corporation shares while 27 reduced holdings. 11 funds opened positions while 25 raised stakes. 61.75 million shares or 0.63% more from 61.36 million shares in 2017Q2 were reported.
First Eagle Inv Mgmt Ltd Liability Corporation reported 0% in Geron Corporation (NASDAQ:GERN). Renaissance Technologies Ltd accumulated 0% or 649,880 shares. Bb&T Secs Llc reported 10,750 shares. Glenmede Co Na stated it has 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Great West Life Assurance Communications Can accumulated 0% or 13,098 shares. Citigroup has invested 0% in Geron Corporation (NASDAQ:GERN). Acadian Asset Ltd Liability Company holds 24,574 shares or 0% of its portfolio. Susquehanna Intll Gru Limited Liability Partnership holds 64,290 shares or 0% of its portfolio. State Of New Jersey Common Pension Fund D owns 870,000 shares for 0.01% of their portfolio. Royal Bank & Trust Of Canada invested in 14,779 shares or 0% of the stock. State Bank Of Mellon has 782,276 shares. Tudor Inv Et Al has 0% invested in Geron Corporation (NASDAQ:GERN) for 34,032 shares. Moreover, Raymond James Financial Svcs Advsr has 0% invested in Geron Corporation (NASDAQ:GERN) for 82,426 shares. Creative Planning invested in 181,713 shares or 0% of the stock. 335 were accumulated by Assetmark.

The stock of Geron Corporation (NASDAQ:GERN) is a huge mover today! The stock increased 5.37% or $0.16 during the last trading session, reaching $3.14. About 2.87M shares traded or 16.61% up from the average. Geron Corporation (NASDAQ:GERN) has risen 13.81% since March 14, 2017 and is uptrending. It has underperformed by 2.89% the S&P500.
The move comes after 8 months positive chart setup for the $499.99M company. It was reported on Mar, 14 by We have $3.27 PT which if reached, will make NASDAQ:GERN worth $20.00 million more.

Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on March, 16 after the close. They expect $-0.04 EPS, up 20.00 % or $0.01 from last year’s $-0.05 per share. After $-0.04 actual EPS reported by Geron Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Geron Corporation (NASDAQ:GERN) Ratings Coverage

Among 3 analysts covering Geron (NASDAQ:GERN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Geron had 5 analyst reports since August 8, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Geron Corporation (NASDAQ:GERN) on Tuesday, August 1 with “Hold” rating. The stock has “Outperform” rating by FBR Capital on Tuesday, September 13. On Monday, December 7 the stock rating was maintained by Piper Jaffray with “Overweight”. Zacks downgraded the stock to “Hold” rating in Saturday, August 8 report. The rating was maintained by MLV on Monday, August 10 with “Buy”.

More recent Geron Corporation (NASDAQ:GERN) news were published by: which released: “Imetelstat Might Be Brought Down By Hy’s Law” on February 20, 2018. Also published the news titled: “Geron: The Good, The Bad And The Ugly” on February 14, 2018.‘s news article titled: “Why Geron Corporation Stock Is Rising Today” with publication date: March 13, 2018 was also an interesting one.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $499.99 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: